Provention Bio, Inc. Common Stock
PRVB
PRVB was delisted on the 26th of April, 2023.
113 hedge funds and large institutions have $176M invested in Provention Bio, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 26 increasing their positions, 37 reducing their positions, and 19 closing their positions.
396% more call options, than puts
Call options by funds: $8M | Put options by funds: $1.61M
33% more capital invested
Capital invested by funds: $133M → $176M (+$43.6M)
11% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 19
1% more funds holding
Funds holding: 112 → 113 (+1)
30% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$6.69M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.24M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$1.23M |
| 4 |
SC
Sessa Capital
New York
|
+$625K |
| 5 |
Morgan Stanley
New York
|
+$533K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.07M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
-$2.43M |
| 3 |
PA
Perceptive Advisors
New York
|
-$938K |
| 4 |
Truist Financial
Charlotte,
North Carolina
|
-$843K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$828K |
PRVB Hedge Fund Activity: Q1 2022 in Review
113 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q1 2022, worth a combined $176M — up 33% from $133M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new PRVB positions and 19 closed out — a net gain of 2 holders — while 26 added to existing stakes and 37 trimmed.
The largest buyer was VR Adviser, opening a new position worth an estimated $6.69M. The largest seller was Millennium Management, exiting entirely with an estimated $3.07M sold.
- 113 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q1 2022, up from 112 in Q4 2021.
- Funds reported $176M of Provention Bio, Inc. Common Stock stock for Q1 2022, up 33% quarter-over-quarter.
- 21 funds opened new Provention Bio, Inc. Common Stock positions in Q1 2022 and 19 closed out, a net change of +2 holders.
- The largest Provention Bio, Inc. Common Stock buyer in Q1 2022 was VR Adviser, an estimated $6.69M added.
- The largest Provention Bio, Inc. Common Stock seller in Q1 2022 was Millennium Management, an estimated $3.07M sold.
Based on aggregated 13F filings for Q1 2022.